DMAC
DiaMedica Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.76
+3.05%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.7x
Market Cap
$364.54M
MomentumView details →
1D Return
+3.05%
YTD Return
−15.94%
RSI (14)
51.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.7x
Market Cap
$364.54M
RSI (14)
51.1
MomentumView details →
1D Return
+3.05%
YTD Return
−15.94%
SummaryUpdated Jun 1, 2026
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Minneapolis, Minnesota. The company was formerly known as DiaMedica Inc. before changing its name in December 2016. DiaMedica focuses on developing novel treatments for neurological and kidney diseases, with its lead drug candidate DM199 currently in Phase 2 and Phase 2/3 clinical trials for stroke and kidney disease applications. The company went public in 2012 and has since expanded its clinical pipeline to include treatments for preeclampsia, representing a significant pivot into pregnancy-related conditions.
Similar companies
Latest newsMore news →
DiaMedica Therapeutics reported its second-quarter progress and financial results, highlighting advancement of DM199 in early-onset fetal growth restriction, preeclampsia, and acute ischemic stroke, and a cash runway expected to extend through 2027.24d agoDiaMedica Therapeutics dosed the first patients in a Phase 2 trial of DM199 for treating fetal growth restriction.73d ago